Toll-like receptors (TLRs) recognise pathogen-associated molecular patterns (PAMPs) to detect the presence of pathogens. In addition to their role in innate immunity, TLRs also play a major role in the regulation of inflammation, even under sterile conditions such as injury and wound healing. This involvement has been suggested to depend, at least in part, on the ability of TLRs to recognise several endogenous TLR ligands termed damage-associated molecular patterns (DAMPs). The liver not only represents a major target of bacterial PAMPs in many disease states but also upregulates several DAMPs following injury. Accordingly, TLR-mediated signals have been implicated in a number of chronic liver diseases. Here, we will summarise recent findings on the role TLRs and TLR ligands in the pathophysiology of liver fibrosis and cirrhosis, viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease and hepatocellular carcinoma, and highlight the potential role of TLR agonists, antagonists and probiotics for the treatment of chronic liver disease.
Statistics from Altmetric.com
Toll-like receptors (TLRs) are a highly conserved group of pattern recognition receptors that function as pathogen sensors in vertebrate and invertebrate species. The recognition of specific signature molecules, termed pathogen-associated molecular patterns (PAMPs), by TLRs is a cornerstone of the innate immune system, and enables it to rapidly mount protective responses against invading pathogens.1–4 In addition to their role in the innate immune system, TLRs contribute significantly to a number of other processes including adaptive immune responses, regulation of sterile inflammation, wound healing, and promotion of epithelial regeneration and carcinogenesis.5–7 TLRs play a major role in liver physiology and pathophysiology due to the liver’s anatomical association with the intestine and its exposure to relatively large amounts of intestinally derived PAMPs in healthy and disease states.8–10
TOLL-LIKE RECEPTOR SIGNALLING
Toll-like receptors and co-receptors
The human TLR family currently consists of 10 members, which are structurally characterised by the presence of a leucine-rich repeat (LRR) domain in their extracellular domain and a toll/interleukin 1 (IL1) receptor (TIR) domain in their intracellular domain.11 The existence of a large number of TLRs enables the innate immune system to discriminate between PAMPs that are characteristic of different microbial classes and launch specific defence mechanisms.11 12 TLR4 is best known for sensing Gram-negative bacteria by detecting lipopolysaccharide (LPS), a membrane component of Gram-negative bacteria. TLR2 senses Gram-positive infection by recognising cell membrane components such as leipoteichoic acid, peptidoglycan, and various lipopeptides and lipoproteins. TLR3 and TLR7 sense viral infections by recognising double-stranded and single-stranded RNA, respectively. TLR9 recognises non-methylated CpG-containing DNA from bacteria and viruses. The molecular basis for ligand recognition is largely unknown but it has been suggested that leucine-rich repeated domains in the extracellular domain of TLRs may be involved in ligand binding.13 Activation of some TLRs such as TLR2 and TLR4 additionally requires the presence of co-receptors. Two of these co-receptors, CD14 and MD-2, also contain leucine-rich repeat domains suggesting their involvement in ligand recognition and binding. Activation of TLR4 by LPS absolutely requires the presence of the co-receptor MD-2 for signalling, whereas some TLR4-mediated signals may still be generated in the absence of CD14.14 MD-2 is not only required for cell-surface expression of TLR4,15 but also appears to be essential for the activation of the TLR4 signalling cascade.16 The most recent model of LPS-mediated TLR4 activation suggests that CD14 catalyses the binding of LPS to the MD-2–TLR4 complex. Binding of LPS to MD-2 induces a conformational change in MD-2 which then allows this complex to bind to a second TLR4 receptor thus achieving TLR4 homo-dimerisation and signalling.17 TLR2 ligands require the presence of CD36 for efficient signal induction by some ligands but the exact role of CD36 in TLR2 signalling remains to be elucidated.18 Although each TLR detects specific ligands, many of the signalling molecules that mediate intracellular response are shared by the TLRs (see fig 1). All TLRs signal through one or two adapter molecules termed myeloid differentiation factor 88 (MyD88) and TIR domain-containing adaptor inducing IFNβ (Trif) which explains why responses to different TLR ligands often generate similar downstream signals.11 12 Thus, it appears that the existence of a large number of TLRs mainly serves to enable an efficient and specific detection of a wide range of PAMPs rather than generating highly tailored immune responses.
TLR-mediated signals are transduced through two major pathways, the “MyD88-dependent pathway” and the “MyD88-independent pathway”. MyD88 is an essential part of the signalling cascade of all TLRs except for TLR3. In contrast, Trif only interacts with TLR3 and TLR4, and is responsible for mediating MyD88-independent signals (see fig 1). Both MyD88-dependent and MyD88-independent pathways initiate the transcription of a specific set of genes involved in pro-inflammatory, antiviral and antibacterial responses.11 In TLR4 signalling, MyD88 mediates an upregulation of inflammatory cytokines through activation of nuclear factor kappa B (NF-κB) whereas the MyD88-independent pathway contributes to both interferon (IFN) upregulation through interferon regulatory factor-3 (IRF-3), and inflammatory gene induction through NF-κB (see fig 1). The MyD88-dependent and the MyD88-independent pathways mediate NF-κB and subsequent inflammatory cytokine production through different mechanisms and kinetics; NF-κB induction in the MyD88-dependent pathway occurs with fast kinetics whereas NF-κB activation in the MyD88-independent pathway occurs with slower kinetics. TLR3 interacts with Trif resulting in an upregulation of IFN and inflammatory cytokines through the MyD88-independent pathway in a similar fashion as the MyD88-independent pathway in TLR4 signalling (see above). In TLR7 and TLR9 signalling, MyD88 induces an IRF-7-dependent upregulation of IFN production and NF-κB-dependent upregulation of inflammatory cytokines. In TLR2 signalling, MyD88 upregulates inflammatory cytokines through an NF-κB-dependent pathway.
Negative regulation of toll-like receptor signalling
Although strong pro-inflammatory and antiviral responses after TLR stimulation may be beneficial in the short term to eradicate pathogens, a prolonged or exaggerated activation of TLR signalling may have deleterious effects. Therefore, several mechanisms have evolved which negatively regulate TLR-induced cellular responses.19 These mechanisms act at the receptor level RP105, ST2 and single immunoglobulin domain-containing IL1 receptor related (SIGGIR) expression, TLR downregulation or degradation), at the level of adapter molecules such as MyD88 and TIR domain containing adaptor protein (TIRAP), or receptor proximal kinases such as IL1 receptor-associated kinase (IRAK). Mechanisms to achieve a reduction in TLR signalling include decreased TLR4 transcription,20 proteolytic degradation of TLR4, TLR 9 and TIRAP after being marked for degradation by the E3 ubiquitin ligase Triad3A21 or suppressor of cytokine signalling-1 (SOCS-1),22 expression of inhibitory TIR-domain containing receptors such as ST2 and SIGIRR23 24 or LRR-domain containing receptors such as RP105,25 and expression of non-functional signalling molecules such as MyD88s,26 27 IRAK-M,28 IRAK2c and IRAK2d.29
TOLL-LIKE RECEPTOR LIGANDS
Pathogen-associated molecular patterns
Early detection of infection is advantageous in mounting an efficient defence against pathogens. Accordingly, even minuscule amounts of PAMPs such as lipopolysaccharide (LPS), lipopeptides, unmethylated DNA, and double-stranded RNA evoke intense inflammatory reactions. Many pro-inflammatory effects of PAMPs are a consequence of TLR-induced secretion of inflammatory mediators such as tumour necrosis factor α (TNFα) and IL1β. Accordingly, PAMPs such as LPS, lipopeptides, dsRNA and unmethylated DNA are among the strongest inducers of TNFα and IL1β release in vitro and in vivo.5 As most bacteria reside in the extracellular space, TLRs that detect bacterial PAMPs such as LPS and lipoproteins are located on the cell surface. Viral RNA and bacterial DNA, but not host DNA, are present in late endosome-lysosomes. Therefore, TLR3, TLR7 and TLR9 are located in these cellular organelles.12 The restriction of TLR ligand recognition to specific cellular compartments such as the cell membrane or lysosomes not only increases chances to encounter specific PAMPs but also decreases the chance of TLRs to be exposed to and aberrantly activated by host molecules, thus adding an additional level of control to ensure proper TLR activation.
Regulation of bacterial translocation by the intestinal barrier
The intestinal microbiota hosts more than 99% of the bacterial mass in the body and is the principal source of bacterially derived PAMPs in health and many disease states. Several protective mechanisms ensure that only a minute amount of bacteria and bacterial products reaches the portal circulation under normal circumstances. These include a thick layer of mucins, secretion of IgA and antimicrobial factors, a tightly sealed epithelial surface and an active mucosa-associated lymphatic tissue (MALT) (see fig 2).30 Accordingly, portal and systemic LPS levels are nearly undetectable in normal rats and healthy people, respectively.31–33 In chronic liver disease, structural changes of the intestinal mucosa such as loss of tight junctions, widening of intercellular spaces, vascular congestion, and defects in the mucosal immune system promote the loss of barrier function and allow increased translocation of bacteria and bacterial PAMPs.30
Whereas the upper gastrointestinal tract is only sparsely populated, microbial density gradually increases distally with about 105 colony-forming units/ml in the jejunum to 108 in distal ileum and caecum, and up to 1012 in the colon.34 Although intestinal anaerobic bacteria outnumber aerobic bacteria by a ratio of 100:1 to 1000:1,34 virtually all translocating bacteria are aerobic.30 In fact, anaerobic bacteria suppress colonisation and growth of potentially invasive microbes and thereby exert an important role in maintaining gastrointestinal health and in reducing the translocation of potentially harmful microbes.35 Accordingly, selective elimination of anaerobic bacteria promotes intestinal bacterial overgrowth and translocation.35 Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, enterococci and streptococci not only represent the species that are most proficient at translocation, but also cause the large majority of infections in patients with cirrhosis.36 37 In cirrhosis, overgrowth of bacteria, especially in locations with low bacterial counts such as the proximal small intestine, and overgrowth of strains with a higher translocation capacity may occur, possibly due to changes in the intestinal motility and the decreased luminal levels of bile acid, a suppressor of bacterial growth.30 Bacterial overgrowth together with the above-described changes in the intestinal mucosal barrier result in an increased rate of bacterial translocation and endotoxaemia.
Damage-associated molecular patterns
Several TLRs not only have the ability to recognise more than one ligand, but often recognise ligands with completely different chemical structures.38 The best examples for the high promiscuity of TLRs are TLR2 and TLR4. TLR4 recognises lipids such as the lipid A portion of LPS as well as proteins from respiratory syncytial virus, vesicular stomatitis virus and mouse mammary tumour virus.39–41 TLR2 recognises a wide range of ligands including lipoteichoic acids, various proteins including lipoproteins and glycoproteins, zymosan and peptidoglycan, as well as lipopolysaccharides from specific bacterial strains.11 38 The ability of TLRs to recognise ligands that are chemically unrelated is believed to be the basis for the activation of TLRs by endogenous ligands. This activation does not occur under normal circumstances but only when there is a change in the environment that either leads to the release of endogenous ligands from a cellular compartment that is usually not in contact with TLRs, or to the modification of endogenous mediator that gives them the ability to activate TLRs.38 42 Due to the association of many endogenous ligands with tissue injury, the nomenclature of damage-associated molecular pattern (DAMP) has been suggested. The best characterised DAMPs include high-mobility group box 1 (HMGB1), hyaluronan, S100 proteins, the alternatively spliced extra domain A of fibronectin, and heat shock protein 60. Most of these ligands act as agonists of TLR2 or TLR4, or both receptors. However, there is still ongoing controversy whether these DAMPs indeed are bona fide TLR ligands since many of them have either been purified in bacterial systems or have a high affinity to bacterial products suggesting that bacterial products or other TLR-activating substances such as lipids or DNA rather than the ligands themselves mediate their TLR-activating effect.43 Further studies including genetic inactivation of candidate molecules are required to characterise DAMPs as bona fide TLR ligands, and it is likely that only some of the above-mentioned candidates will be confirmed as TLR ligands. Furthermore, it has been suggested that endogenous DNA can act as a TLR9 agonist to promote autoimmune reactions.5 HMGB1 and hyaluronan from eukaryotic sources have been shown to activate TLRs thus largely excluding bacterial contaminants as mediators of TLR signals.44 45 Moreover, HMGB1 and hyaluronan are elevated in liver disease and HMGB1 plays a potential role in the pathophysiology of liver disease.46 47 For these reasons, we will limit further discussion on TLR-activating DAMPs to HMGB1 and hyaluronan.
Release of damage-associated molecular patterns
Release of DAMPs into the extracellular space is achieved by a number of different mechanisms that involve (1) leakage from necrotic cells, (2) increased synthesis and post-translational modification in response to inflammation, and (3) degradation of inactive precursors into TLR-mimetic degradation products in inflammatory environments.
High mobility group box 1
HMGB1 is a DNA-binding protein that induces bends in the helical DNA structure to facilitate multiple physical interactions of DNA with transcription factors, recombinases and steroid hormone receptors, and to thus allow transcription and other nuclear transactions to take place.48 In addition to this transcription factor-like function, HMGB1 also has cytokine-like effects that require its presence in the extracellular space.48 49 Release of HMGB1 into the extracellular space is mediated by two mechanisms.
The first mechanism involves acetylation of many of its 43 lysine residues that lie in proximity to its two nuclear-localisation signals thus reducing interaction with the nuclear importer protein complex, preventing nuclear re-entry and promoting secretion of HMGB1.50 This active HMGB1 secretion process seems to occur predominantly in inflammatory cells.
The second mechanism is the passive diffusion of HMGB1 from cells that undergo necrosis.51 Importantly, HMGB1 release does not occur from apoptotic cells, presumably because HMGB1 is tightly bound to cruciform DNA and hypo-acetylated proteins within the nucleus of the apoptotic cell whereas it is only loosely bound to DNA in necrotic cells.49 Thus HMGB1 has been suggested to be a signature DAMP that signals the presence of necrosis, and subsequently triggers inflammation.51
Hyaluronan is a negatively charged high molecular weight glycosaminoglycan, which is ubiquitously distributed in the extracellular matrix and is a component of the basement membrane. At sites of inflammation and tissue destruction, high molecular weight hyaluronan can be broken down to lower molecular weight hyaluronan fragments via oxygen radicals and enzymatic degradation. In contrast to high molecular weight hyaluronan, low molecular weight hyaluronan has cytokine-like properties, and induces inflammatory gene expression in epithelial cells, endothelial cells, fibroblasts, dendritic cells, and macrophages.52 In the extracellular space, hyaluronan is bound by the CD44 receptor which mediates some of its pro-inflammatory effects. However, hyaluronan is able to stimulate chemokine production in the absence of CD44.45 Since the disruption of basement membranes is typically associated with injury, it has been suggested that the recognition of low molecular weight hyaluronan by TLRs and other receptors is part of an injury recognition system.
EXPRESSION OF TOLL-LIKE RECEPTORS IN THE LIVER
Due to its anatomical links to the gut, the liver is constantly exposed to gut-derived bacterial products, and functions as a major filter organ and a first line of defence. Eighty per cent of intravenously injected endotoxin is detected in the liver within 20–30 min.53 54 Moreover, the liver is an important site for bacterial phagocytosis and clearance as it hosts more then 80% of the body’s macrophages. Kupffer cells, the resident macrophages of the liver, are able to efficiently take up endotoxin and phagocytose bacteria carried through the portal vein and are considered to play a major role in the clearance of systemic bacterial infection.55 56 The healthy liver contains low mRNA levels of TLRs such as TLR1, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TLR10 and signalling molecules such as MD-2 and MyD88 in comparison to other organs,57–59 suggesting that the low expression of TLR signalling molecules may contribute to the high tolerance of the liver to TLR ligands from the intestinal microbiota to which the liver is constantly exposed.
Kupffer cells, the resident macrophages of the liver, play a crucial role in host defence which is linked to their ability to phagocytose, process and present antigen, and secrete various pro-inflammatory mediators including cytokines, prostanoids, nitric oxide and reactive oxygen intermediates.55 56 60 Kupffer cells are among the first cells in the liver to be hit by gut-derived toxins such as LPS and orchestrate inflammatory responses within the liver. Accordingly, Kupffer cells express TLR4 and are responsive to LPS.61 Although some studies have demonstrated that Kupffer cells are involved in the uptake and hepatic excretion of LPS,62 63 others have shown that Kupffer cell depletion does not reduce LPS clearance.64 Moreover, Kupffer cells can inactivate LPS by deacetylation.65 Following stimulation with LPS at concentrations between 0.1 and 1000 ng/ml, Kupffer cells produce TNFα, IL1β, IL6, IL12, IL18 and several chemokines.66 Notably, Kupffer cells mediate the majority of cytokine and chemokine expression in liver after LPS injection (25 μg intraperitoneally) as demonstrated by depletion experiments.67 Kupffer cells also functionally express TLR2, TLR3 and TLR9.68–71 In comparison to peripheral blood monocytes, Kupffer cells express low levels of CD14.58 Moreover, freshly isolated human Kupffer cells secrete the anti-inflammatory cytokine IL10 in response to stimulation with LPS, which contributes to the downregulation of pro-inflammatory cytokines.72 Thus, Kupffer cells may have a higher LPS tolerance to adapt to the special circumstances in their anatomical location that is frequently hit with low levels of LPS even under normal conditions.
Hepatocytes fulfil metabolic and detoxifying functions in the liver, and are important mediators of the acute phase response. Hepatocytes express TLR4 receptors and are responsive to LPS, but this response is fairly weak with only 2-fold elevated levels of serum amyloid A and a less than 2-fold induction of most upregulated genes in a microarray after LPS. Moreover, doses of 100 ng/ml and higher were required to see significant effects in hepatocytes.73 74 Similarly, stimulation with TLR2 ligands induces NF-κB activation and a weak induction of serum amyloid A.74 The expression of TLR2 in hepatocytes is upregulated by LPS, TNFα, bacterial lipoprotein and IL1β in an NF-κB-dependent manner indicating that hepatocytes become more responsive to TLR2 ligands under inflammatory conditions.74 In contrast, TLR4 expression in hepatocytes is not upregulated by pro-inflammatory mediators.75 Hepatocytes play a major role in the uptake of LPS and its removal from the systemic circulation by secreting LPS into the bile.62 64 Clearance of LPS occurred at a similar rate in rats that had been depleted of Kupffer cells by gadolinium chloride indicating that hepatocytes are the principal mediators of this process.64 A recent study demonstrated that TLR4, CD14 and MD-2 are required for the uptake of LPS by hepatocytes.76 Interestingly, TLR4 signalling is not required for this process as hepatocytes from TLR4-deficient C3H/HeJ mice were as efficient as those isolated from TLR4-sufficient C3H/HeOuJ mice to take up LPS.76 Although this study clearly demonstrated the ability of hepatocytes to take up LPS, the uptake of LPS in vivo through this TLR4-dependent mechanism remains to be proven.
Hepatic stellate cells
Following liver injury, hepatic stellate cells undergo an activation process and become the predominant extracellular matrix-producing cell type in the liver.77 Activated human hepatic stellate cells express TLR4 and CD14 and respond to LPS with the activation of IκB kinase (IKK)/NF-κB and JNK as well as the secretion of pro-inflammatory cytokines.78 Activated mouse hepatic stellate cells express TLR2, TLR4 and TLR9 and respond to LPS, lipoteichoic acid, N-acetyl muramyl peptide and CpG–DNA with an upregulation of extracellular-related kinase (Erk) phosphorylation and IL6, transforming growth factor β1 (TGFβ1) and monocyte chemoattractant protein-1 (MCP-1) secretion.47 79–81 Quiescent murine hepatic stellate cells express as much TLR4 as in vivo-activated hepatic stellate cells (HSCs) and are highly responsive to LPS, even at doses as low as 1 ng/ml.47 Moreover, quiescent HSCs activate NF-κB in response to LPS injection (0.1 mg/g intraperitoneally) in vivo.47 Notably, LPS downregulates the TGFβ pseudoreceptor Bambi in quiescent HSCs to promote TGFβ signalling and stellate cell activation.47
Biliary epithelial cells
Biliary epithelial cells line the biliary tree which connects the liver with the intestinal lumen to deliver bile to the intestine. Mouse biliary epithelial cells express CD14, MD-2 and TLR2, TLR3, TLR4 and TLR582 and display NF-κB activation and TNFα production after LPS (1 μg/ml) stimulation,82 and an increase in CDX2 and mucus core protein-2 (MUC2) following TLR2 or TLR4 stimulation.83 Human biliary epithelial cells express TLR1–10.84 85 In an in vitro model of biliary cryptosporidiosis, C parvum recruits TLR2 and TLR4 to the host-cell–parasite interface, and induces NF-κB activation, IL8 and human β-defensin 2 expression.84
Sinusoidal endothelial cells
Sinusoidal endothelial cells form the fenestrated lining of the hepatic sinusoids and thus have an important function in hepatic perfusion and nutrient supply. Sinusoidal endothelial cells constitutively express TLR4 and CD14 as well as TLR9, and show an increase in NF-κB activation after LPS (10 ng/ml) stimulation.86 87 Moreover, mRNA for TLR1–9 was detected in sinusoidal endothelial cells and functional expression of TLR3 has been demonstrated by the ability of supernatants from poly-I:C treated sinusoidal cells to reduce hepatits B virus (HBV) replication in immortalised hepatocytes.88 After repetitive LPS challenges, sinusoidal endothelial cells show reduced NF-κB activation, CD54 expression and a reduced ability to promote leucocyte adhesion.86 In sinusoidal endothelial cells, LPS tolerance is not regulated at the level of TLR4 surface expression, but appears to be linked to prostanoid expression.86 Although some authors propose sinusoidal endothelial cells to be involved in the hepatic uptake of LPS, other studies have not found such a role.62 64
Hepatic dendritic cells
Hepatic dendritic cells (DCs) are the professional antigen-presenting cells of the liver. During inflammation, DCs are recruited into the liver sinusoids from where they can migrate to periportal and pericentral areas. Like other DCs, hepatic DCs express TLR2 and TLR4.57 89 While one study found a lower expression of TLR4 on hepatic DCs in comparison to their splenic counterparts,57 another study reported a higher expression of TLR2 and TLR4 on hepatic cDCs and increased TNFα and IL6 after peptidoglycan (PGN) and LPS (10 μg/ml) stimulation.89 However, both studies reported a weaker stimulation of naive allogeneic CD4+ T cells by hepatic DCs in comparison to splenic DCs.57 89
ROLE OF TOLL-LIKE RECEPTORS IN CHRONIC LIVER DISEASE
Alcohol-induced liver injury
Acute and chronic ingestion of alcohol lead to a strong elevation of portal and systemic levels of endotoxin in animal models and humans.31–33 Whereas healthy controls display only 2.5 pg/ml of endotoxin in peripheral blood, patients with alcoholic fatty liver, alcoholic hepatitis and alcoholic cirrhosis display 14 pg/ml, 16 pg/ml and 19 pg/ml endotoxin in peripheral blood.31 Interestingly, acute ingestion of alcohol in rats leads to significantly higher levels of portal endotoxin than systemic levels with concentrations of 30–80 pg/ml in the portal vein 2 h after gavage.33 90 Thus, peripheral measurements are likely to underestimate the amount of endotoxin that targets the liver, most likely due to the efficient clearance of endotoxin by the liver. Endotoxin is a crucial mediator of liver injury in alcoholic liver disease as demonstrated by the significant reduction of alcoholic liver injury following elimination of the Gram-negative microbiota by antibiotics,91 and the sensitisation to LPS-induced liver injury following long-term ethanol exposure.92 The elevation of endotoxin appears to be predominantly caused by two mechanisms (see fig 3). First, alcohol consumption leads to changes in the intestinal microbiota with upper gastrointestinal tract bacterial overgrowth being more than six times more frequent in people who are very heavy drinkers than in people who to not drink heavily.93 94 However, the effects of alcohol on the composition of the intestinal microbiota have not been studied in detail. Second, a large body of literature has clearly documented that alcohol ingestion disrupts the intestinal epithelial barrier causing enhanced permeability95–97 thus allowing increased levels of LPS to enter the portal circulation. It has been suggested that the intestinal microbiota converts ethanol into acetaldehyde which in turn disrupts tight junctions and increases paracellular permeability.98 99
Kupffer cells have been established as a crucial cellular target of LPS in ethanol-induced liver injury as demonstrated by a strong reduction of alcoholic liver injury following depeletion of Kupffer cells with gadolinium chloride.100 Moreover, the activation of Kupffer cells in alcoholic liver disease largely depends on TLR4 since TLR4-mutated C3H/HeJ mice as well as TLR4-deficient mice display strongly reduced levels of pro-inflammatory mediators in the liver and blunted liver injury despite elevated endotoxin levels.101 102 The TLR4-mediated signal in alcoholic liver injury is mediated through a MyD88-independent pathway,102 most likely through the adapter molecule Trif (see fig 3). NADP(H) oxidase is a crucial downstream mediator of TLR4 in Kupffer cells during alcohol-induced liver injury, as mice deficient in p47phox, the main cytosolic component of NADP(H) oxidase, show an absence of free-radical production, NF-κB activation, TNFα mRNA induction and liver pathology after ethanol treatment.103
Non-alcoholic fatty liver and steatohepatitis
There is accumulating evidence that the intestinal microbiota plays an essential part in the promotion of hepatic fat accumulation. Ob/ob mice as well as obese humans have a different composition of their caecal microbiota in comparison to lean controls.104 105 One mechanism by which the altered composition of the intestinal microbiota in ob/ob mice as well as in humans promotes obesity and fatty liver is TLR-independent through an increased bacterial capacity for energy harvest.106 A second mechanism by which the altered intestinal microbiota may promote obesity and fatty liver is an increase in LPS-containing microbiota107 and increased intestinal permeability to LPS.108 Accordingly, a 4-week high-fat diet increased plasma LPS concentration two to three times.107 Notably, subcutaneous infusion of a low dose of LPS resulted in excessive weight gain, insulin resistance and increase liver triglycerides in mice.107 Vice versa, selective intestinal decontamination results in decreased endotoxin levels in mice on a high-fat diet,109 and improved glucose tolerance and reduced hepatic triglycerides in mice with diet-induced obesity as well as in ob/ob mice.110
In addition to its role in hepatic fat accumulation, LPS is also involved in the development of non-alcoholic steatohepatitis (NASH). A crucial role for LPS signalling in NASH was first demonstrated by the increased hepatic sensitivity of genetically obese Fa/Fa rats and ob/ob mice to low doses of LPS.111 This finding has been further confirmed in TLR4-mutant mice that display decreased injury and lipid accumulation following a methionine–choline-deficient (MCD) diet, a model of NASH.112 In contrast, TLR2-deficient mice are not protected from steatohepatitis after the MCD diet.113 The predominant role of TLR4 signalling in NASH is further emphasised by the ability of the TLR4 ligand LPS but not the TLR2 ligand peptidoglycan to exacerbate liver injury in mice treated with a MCD diet.113 Notably, probiotics reduce hepatic injury and inflammation in ob/ob mice114 suggesting that modulation of the gut microbiota by probiotics may represent a feasible approach for the prevention or treatment of NASH.
Hepatic fibrosis and cirrhosis
Chronic liver injury leads to the development of hepatic fibrosis, the increased accumulation of extracellular matrix in the liver, and hepatic cirrhosis, an advanced stage of hepatic fibrosis in which functional liver tissue is largely replaced by extracellular matrix and regenerating nodules. The development of hepatic fibrosis and cirrhosis occurs in virtually any type of chronic hepatic injury including viral hepatitis, alcohol, autoimmune and metabolic disease.77 There is abundant data demonstrating that LPS is elevated in experimental models of hepatic fibrosis47 115 116 and in patients with cirrhosis.31 117 118 Whereas healthy subject displayed endotoxin levels of less than 3 pg/ml, patients with Child–Pugh classes A, B and C had endotoxin levels of 4.9 pg/ml, 7.9 pg/ml and 10.2 pg/ml, respectively.118 It is believed that changes in intestinal motility, subsequent alterations of the intestinal microbiota, decreased mucosal integrity and suppressed immunity in hepatic fibrosis contribute to a failure of the intestinal mucosal barrier and cause increases in bacterial translocation and LPS levels in later stages of hepatic fibrosis and cirrhosis.30 119–123 Studies from the 1950s have shown that antibiotics prevent hepatic injury and fibrosis induced by CCl4 treatment or a choline-deficient diet, and that endotoxin enhances hepatic fibrosis induced by a choline-deficient diet.124 125 Recent studies using TLR4-mutant as well as gut-sterilised, CD14- and LPS binding protein (LBP)-deficient mice have demonstrated the crucial role for the LPS–TLR4 pathway in hepatic fibrogenesis.47 126 TLR4-mutant mice display a profound reduction in hepatic fibrogenesis in three different experimental models of biliary and toxic fibrosis.47 The crucial role of LPS is supported by the finding that LBP-deficient as well as gut-sterilised mice also have a marked reduction of hepatic fibrosis.47 126 In addition to LPS, endogenous TLR ligands such as hyaluronan and HMGB1 are also elevated in murine fibrogenesis.47 However, in view of the crucial role of the intestinal microbiota in hepatic fibrogenesis, their contribution is at best moderate. Accordingly, the inhibition of HMGB1 signalling by a blocking antibody did not improve biliary fibrogenesis (RFS, unpublished results). In contrast to TLR4, TLR2-deficient mice did not show a profound reduction in hepatic fibrosis following bile duct ligation.47 TLR4 is expressed on two key mediators of hepatic fibrogenesis: Kupffer cells and hepatic stellate cells.47 61 78 Kupffer cells initiate fibrogenesis by secreting pro-inflammatory and pro-fibrogenic cytokines, while hepatic stellate stells are the predominant source of extracellular matrix production in the fibrotic liver.77 Although Kupffer cells express the highest levels of TLR4 in the liver and are considered a prime target of LPS, TLR4 expressed on quiescent and activated hepatic stellate cells is the main mediator of fibrosis as demonstrated in TLR4-chimeric mice.47 LPS directly targets hepatic stellate cells in vivo to upregulate chemokines and attract Kupffer cells. At the same time, TLR4 activation induces a downregulation of the TGFβ pseudoreceptor Bambi on hepatic stellate cells. These two mechanisms work hand in hand to promote the activation of hepatic stellate cells by Kupffer cell-released TGFβ, and subsequently hepatic fibrosis (see fig 4).47 126 Notably, a recent study has identified a single nucleotide TLR polymorphism that results in a T399I substitution and confers a significantly reduced risk for fibrosis progression in patients with chronic hepatitis C virus infection.127 This polymorphism is associated with a reduced TLR4 responsiveness thus confirming the profibrogenic role of TLR4 in a clinically relevant setting. Two recent studies also demonstrated that hepatic stellate cells express TLR9, and that TLR9-deficient mice display decreased hepatic fibrosis.80 128 The decrease in hepatic fibrosis was linked to the ability of TLR9-expressing hepatic stellate cells to recognise apoptotic hepatocytes resulting in stellate cell activation.128
TLRs may also modulate several of the complications of hepatic fibrosis. Probiotics and selective intestinal decontamination decrease hepatic encephalopathy in rodent models as well as in patients.129–131 However, it is not clear whether this effect is mediated through TLR-dependent mechanisms as probiotic treatment led not only to a significant reduction of endotoxin but also of the ammonia, a principal mediator of encephalopathy.132 Moreover, LPS has been implied in the regulation of blood pressure in cirrhosis. In two studies, selective intestinal decontamination significantly decreased endotoxin levels and improved the hyperdynamic circulatory state of cirrhosis but did not significantly reduce the hepatic venous pressure gradient.133 134 In another study, there was no decrease in hepatic venous pressure gradient in patients with significant portal hypertension but none of the involved patients had detectable serum endotoxin levels.135
The liver is probably the best example for the link between chronic inflammation and cancer that was postulated by Rudolf Virchow more than 100 years ago.136 Almost 80% of hepatocellular cancers (HCCs) in the Western world develop as a consequence of chronic inflammation and arise in fibrotic or cirrhotic livers.137 The involvement of TLR signalling in fibrosis-associated HCC has not yet been investigated. However, there is a high probability that fibrosis-associated HCC is mediated by TLR signalling as TLR4 and MyD88 are required for the development of fibrosis,47 a predisposing condition for HCC development. An important role for the TLR signalling molecule MyD88 was shown in diethylnitrosamine (DEN)-induced HCC in male mice,138 but this tumour-promoting pathway is mediated by IL1R, another upstream activator of MyD88.139 Therefore, it is possible that DEN-induced non-fibrotic HCCs and fibrosis-associated HCCs may both be MyD88-dependent but mediated by different signalling cascades.
Hepatitis C virus infection
Hepatitis C affects approximately 3.2 million people within the United States and 170 million people worldwide.140 About 30% of patients chronically infected with hepatitis C virus (HCV) show signs of active hepatic inflammation, and are at risk of developing fibrosis, cirrhosis and HCC. Accordingly, hepatitis C continues to be one of the leading indications for liver transplantation in the United States.141
Patients with chronic HCV infection display more than 10-fold-increased serum levels of endotoxin with <5 pg/ml in healthy controls and >50 pg/ml in chronic HCV patients with mild-to-moderate hepatic inflammation and less than 25% incidence of hepatic fibrosis.142 Moreover, several HCV ligands act as TLR agonists.143 144 However, HCV has developed strategies to avoid activation of antiviral pathways by TLRs and their ligands: HCV selectively impairs innate immune pathways that limit HCV replication such as type I IFNs (see fig 5) while at the same time generating a chronic inflammatory state that causes persistent liver injury.145 146 When double-stranded RNA from HCV binds to TLR3 within the endosome, the expected response would be activation of TRIF and subsequent upregulation of IFNβ through tank-binding protein kinase-1 (TBK-1)/IKKϵ and IRF-3. However, the IFNβ response is strongly inhibited by a mechanism that involves the cleavage of TRIF by non-structural HCV protein NS3/NS4A.147 Furthermore, NS3 binds directly to TBK-1, disrupting the activation of IRF-3 and the upregulation of IFNβ.148 Thus, HCV inhibits the ability of the TLR-3 pathway to upregulate IFNβ and hinders viral clearance by two distinct mechanisms. In addition to disrupting the function of TLR3, HCV also affects the function of other TLRs integral to the viral and immune response. In vitro studies utilising a murine macrophage line that stably expresses HCV proteins, demonstrate that expression of HCV proteins inhibits the signalling pathways of TLR2, TLR4, TLR7 and TLR9. Specifically, these studies showed that the NS5A inhibits TLR signalling by binding to the adaptor protein MyD88 and inhibiting the recruitment of IRAK-1 leading to a decrease in MyD88-dependent signals.149 Myeloid dendritic cells from patients with chronic HCV display an increased expression of TLR2 and TLR4, but a decrease in the cytokine response to TLR agonists150 thus confirming the impairment of TLR signalling by HCV in primary cells. Cell culture produced HCV impairs TLR9-induced IFNα production in plasmacytoid dendritic cells, but has no effect on TLR3- and TLR4- myeloid and monocyte-derived dendritic cells suggesting that HCV may specifically target plasmacytoid dendritic cells.151 Accordingly, TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection.152 Thus restoration or boosting of TLR signalling pathways that are related to HCV eradication may be a promising treatment strategy. Accordingly, 1 week of treatment with the TLR7 agonist isatoribine caused a significant reduction of plasma HCV RNA, an increase in the levels of 2′,5′-oligoadenylate synthetase, a marker of antiviral immunity, and an increase in the levels of the chemokine IP-10 and neopterin, a marker of macrophage activation.153
While certain TLR pathways, especially those that are related to viral clearance, are inhibited by HCV, other TLR signalling pathways may be activated by HCV and thus promote chronic inflammation. For example, hepatitis C core protein and NS3 were found to activate TLR signalling via TLR2, a response that was abrogated in monocytes isolated from MyD88 or TLR2 deficient mice.143 Another study utilising B cells from patients infected with HCV as well as an immortalised lymphoma cell line, demonstrated increased TLR4 expression and higher levels of IFNβ and IL6 in HCV cells in comparison to controls.154 HCV core and NS3 proteins have also been shown to produce both pro- and anti-inflammatory cytokines (TNFα and IL10) in human macrophages through the TLR2/1 and TLR2/TLR6 heterodimers.144 Moreover, macrophages from HCV patients do not display tolerance to LPS after pre-treatment with different TLR ligands, leading to persistent macrophage activation and cytokine release.142 In summary, the current data support the hypothesis that there is a decreased activation of TLR signalling pathway related to virus eradication but an increased activation of TLR signalling pathways related to inflammation. It is likely that this constellation promotes virus expansion, inflammation and potentially the progression to fibrosis and cirrhosis.
Hepatitis B virus (HBV) causes a chronic infection in about 10% of adults exposed to the virus affecting about 1.25 million people within the United States and 370 million people worldwide.155 One study reported a 24-fold induction in endotoxin levels in acute HBV infection, and a 72-fold induction of endotoxin levels in chronic HBV infection.156 Moreover, it has been suggested that HBV contains TLR ligands.157 Several TLRs block HBV replication through their ability to upregulate IFNs. In HBV transgenic mice, activation of TLR3 by poly-I:C leads to an IFN-dependent inhibition of HBV replication.158 These findings have been extended in two recent studies which demonstrated reduced HBV replication after injection of TLR3, TLR4, TLR5, TLR7 and TLR9 ligands into HBV transgenic mice,159 and the ability of supernatants from non-parenchymal cells stimulated with TLR3 and TLR4 agonists to repress HBV replication.88 In a recent clinical study, TLR1–10 receptor expression was quantified in patients with chronic hepatitis B and compared to healthy controls. This study demonstrated that TLR1, TLR2, TLR4 and TLR6 were downregulated in HBV-infected peripheral blood monocytes, and these cells also had a decreased cytokine response to TLR2 and TLR4 ligands.160 Interestingly, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B decreases TLR2 expression in peripheral monocytes, Kupffer cells and hepatocytes whereas HBeAg-negative chronic hepatitis B is associated with increased TLR2 expression suggesting a direct effect of the HBeAg on TLR2 expression.161 Thus, it appears that HBV has developed abilities to downregulate TLRs and thus avoid antiviral pathways, but that prolonged infection and loss of HBeAg may upregulate TLR signalling pathways such as TLR2 that are not involved in anti-HBV responses but promote hepatic inflammation and disease progression. Independently of their effect on HBV replication, TLR7 and TLR9 agonists may also have a role as adjuvants in vaccines in hepatitis B as they boost cellular and humoral responses to HBsAg as single agents or in combination in mice.162–164 However, these results still require confirmation in humans.
Hepatic autoimmune diseases
The liver is known to be a classical immunoprivileged site. Notably, activation of TLR3 is required for infiltration of CD8+ T cells and liver disease after injecting mice with activated liver-specific effector CD8+ T cells, suggesting that TLR signals may represent an important trigger to overcome this immunoprivilege and induce hepatic autoimmune disease.165
Primary biliary cirrhosis (PBC) is an autoimmune disorder usually affecting middle-aged adult women which causes severe injury to the interlobular bile ducts.166 Biliary epithelial cells are known to express TLRs, but under normal conditions are tolerant to antigenic exposures.85 Although biliary epithelial cells isolated from livers from patients with PBC express similar levels of TLRs compared to controls, they secreted higher levels of chemokines when stimulated with TLR3 agonist poly-I:C and co-cultured with liver-infiltrating mononuclear cells.167 Moreover, TLR3 and IFNα/β have been found to be elevated in the portal tracts and liver parenchyma of patients with PBC when compared to control patients with autoimmune hepatitis and hepatitis C.168 In addition, peripheral blood monocytes isolated from patients with PBC have been found to be hyper-responive to TLR ligands.169 170 TLRs may also play a role in B cell proliferation in PBC. Peripheral blood monocytes taken from PBC patients and stimulated with the TLR9 ligand CpG have been shown to induce IgM-producing B cells and an increased expression of TLR9 on these cells.171 172 Although high IgM levels are a typical feature of PBC, the relevance of the induction of IgM-producing B cells by CpG in PBC needs to be further investigated. There are only limited data on the role of TLRs in primary sclerosing cholangitis (PSC), an autoimmune disease that leads to fibro-obliterative changes within the intrahepatic and extrahepatic biliary tract. Stimulating isolated biliary epithelial cells with anti-biliary epithelial cell antibodies from patients with PSC leads to upregulation of TLR4 and TLR9, and a dramatically increased secretion of inflammatory cytokines under baseline conditions, and in the presence of LPS or CpG DNA.173
TARGETING TOLL-LIKE RECEPTORS IN CHRONIC LIVER DISEASE
In recent years, a number of different approaches have been developed to modulate TLR signalling. These approaches include modulation of TLR ligand release from the intestinal microbiota by probiotics and antibiotics, activation of TLR signalling by synthetic TLR ligands and inhibition of TLR activation by small molecule inhibitors. Many of these recently developed agents have undergone evaluation in tissue culture experiments, mouse models and clinical trials, but their efficacy and clinical usefulness have not been proven beyond doubt in large sets of patients with liver disease.
Several small molecule inhibitors of TLR4 have been discovered and are currently being tested in human studies. Some of these inhibitors are lipid A mimetics which bind to the TLR4–MD2 complex but lack intrinsic activity, and thus prevent binding of the lipid A portion of LPS and subsequent TLR4 activation. The crystal structure of the TLR4–MD2 complex with bound “TLR4 antagonist” E5564 (Eisai, Ridgefield Park, New Jersey, USA) was recently published suggesting that the mechanism of action of E5564 is binding through a large internal pocket in MD-2.17 Thus, lipid A mimetic small molecule inhibitors should actually be classified as MD-2 inhibitors. In vitro, E5564 dose-dependently inhibited LPS-mediated activation of primary cultures of human myeloid cells and mouse tissue culture macrophage cell lines as well as human or animal whole blood at nanomolar concentrations as measured by production of tumour TNF and other cytokines. In vivo, E5564 blocked induction of LPS-induced cytokines and LPS or bacterial-induced lethality in primed mice, and cytokine induction and symptoms after endotoxin injection in healthy volunteers.174 175 CRX-526 (Corixa, Seattle, Washington, USA (now part of GlaxoSmithKline)) is another lipid A mimetic antagonist of TLR4 signalling that has been shown to inhibit IL6 and macrophage inflammatory protein (MIP)-1α production after LPS stimulation in vitro, and to almost completely suppress LPS-induced TNFα release in vivo.176 Moreover, CRX-526 reduced colitis in the dextran sodium sulfate and multidrug resistance 1a (MDR1a)-deficiency models of colitis.176 TAK-242 (Takeda Pharmaceutical, Deerfield, Illinois, USA) represents a second class of TLR4 antagonists.177 TAK-242 exerts its inhibitor effects at the intracellular domain of TLR4 as demonstrated by a study in which the extracellular domain of TLR4 was replaced by CD4 to create a constitutively active receptor chimera.178 Activity of this receptor chimera was inhibited by TAK-242 providing evidence that its inhibitory effect does not require the presence of the TLR4 extracellular domain.178 TAK-242 prevented increases in serum levels of wide range of cytokines in mice injected with LPS, and protected mice from LPS-induced lethality.179 Interestingly, TAK-242 showed beneficial effects even when administered after LPS challenge.179 Both E5564 and TAK-242 are currently being tested in phase III clinical trials in patients with septic shock.180 To the best of our knowledge, none of the TLR4/MD-2 inhibitors have been tested in chronic liver disease. Based on the involvement of TLR4 in fibrogenesis, alcoholic liver injury and NASH, small molecule inhibitors of TLR4 might be attractive candidates for the treatment or prevention of these diseases.
Toll-like receptor 7 agonists
The guanosine analogue isatoribine (Anadys Pharmaceuticals, San Diego, California, USA) is a small molecule ligand of TLR7.181 In a recent phase 1 trial in patients with chronic HCV infection, isatoribine induced a significant reduction of plasma HCV.153 Eight out of 12 patients treated with 800 mg intravenous injection of isatoribine once daily for 7 days displayed a decrease of more than 0.5 log10 units with a mean change of −0.76 log in all 12 patients.153 The reduction of viral load was correlated with an induction of markers of a heightened immune antiviral state, including a 7.6-fold induction of 2′,5′-oligoadenylate synthetase levels. This upregulation is comparable to that reported during the first week after the start of treatment with pegylated IFNα-2b. Side effects of isatoribine were mild to moderate and similar to those observed in patients treated with interferon-based therapies. Thus, TLR7 agonists such as isatoribine may represent good candidates for antiviral treatment, potentially in combination with other antiviral compounds. Recently, an oral prodrug of isatoribine, ANA975, was developed and may thus represent a novel oral treatment approach for patients with chronic HCV infection.182 In contrast to isatoribine, the TLR7 and TLR8 agonist resiquimod appears to lack antiviral effects in HCV-infected patients as reported in a preliminary study.183
Toll-like receptor 9 agonists
CPG 10101 (Actilon; Coley Pharmaceutical Group, Ottawa, Ontario, Canada (now part of Pfizer)) is a synthetic oligodeoxynucleotide that has been optimised to stimulate human TLR9. In a multicentre phase 1b trial involving 60 patients with HCV infection, CPG 10101 induced a decrease in HCV RNA a greater than 1 log reduction in 22 of 40 patients who received more than 1 mg CPG 10101, and was thus similar to that reported for pegylated IFN monotherapy.184 Moreover, CPG 10101 dose-dependently induced surrogate markers of antiviral immunity such as IFNγ-inducible protein 10 (IP-10) and IFNα as well as a sustained increase 2′,5′-oligoadenylate synthetase.185 CPG 10101 was well tolerated, and adverse events were consistent with the mechanism of action of CPG 10101. Although data from this study suggest CPG 10101 to be a good candidate for further studies in chronic HCV infection, development of CPG 10101 as treatment for HCV in conjunction with pegylated IFN and/or ribavirin has been temporarily suspended for unknown reasons.185
Summary Box 1
Toll-like receptors (TLRs) are a cornerstone of the innate immune system and provide an almost instant anti-microbial response to fight pathogens.
TLRs are pattern recognition receptors that detect the presence of minute amounts of signature molecules present in pathogens (pathogen-associated molecular patterns (PAMPs)).
Activation of TLRs activates antiviral and pro-inflammatory signalling pathways.
TLRs signal through the adapter molecules myeloid differentiation factor 88 (MyD88), TIR domain-containing adaptor inducing IFNβ (Trif) or both to activate the “MyD88-dependent” and “MyD88-independent” signalling pathways.
It has been suggested that TLRs may also be activated by endogenous ligands. Many of these endogenous ligands are associated with injury and inflammation and belong to a group of molecules termed damage-associated molecular patterns (DAMPs). However, none of these molecules has been proven a bona fide TLR ligand beyond doubt.
Probiotics and antibiotics
Modulation of the intestinal microbiota is an emerging strategy to reduce bacterial translocation and circulating endotoxin levels, and potentially those of other bacterially derived TLR agonist. A number of different approaches have been taken to achieve this goal. Modulation of the enteric microbiota by probiotics or synbiotics, a combination of probiotics with prebiotics, has been demonstrated to reduce bacterial translocation,186–188 circulating endotoxin levels in animal models,132 and bacterial infection, a surrogate marker for bacterial translocation, in patients with hepatic cirrhosis.189 190 In liver cirrhosis, probiotics have shown positive effects on several parameters including the improvement of liver function, prevention of infection, improvement of the hyperdynamic circulation and prevention of hepatic encephalopathy.132 Other areas in which probiotics have positive effects on liver injury and alanine aminotransferase (ALT) levels are (1) NASH with positive effects on ALT levels and liver histology in one mouse and one human study;114 191 (2) alcoholic liver injury;192 and (3) LPS-induced liver injury.187 188 One problem is that a number of studies are relatively small and many of these are uncontrolled studies. The large number of probiotic strains and combinations of strains represents a second important problem, and it will require additional studies to confirm and ideally compare the efficacy of these probiotic strains or combinations for specific liver diseases. Among the most commonly used strains and combinations of strains are: (1) VSL#3, a combination of Streptococcus thermophilus, Bifidobacterium breve, B longum, B infantis, Lactobacillus acidophilus, L plantarum, L casei and L bulgaricus, which has shown efficacy in reducing liver injury in patients with forms of chronic liver disease,191 in a mouse model of NASH,114 and in a mouse model of LPS-induced liver failure;187 (2) Synbiotic cocktail 2000, a combination of Pediococcus pentosaceus, Leuconostoc mesenteroides, L paracasei F19, L plantarum 2592 plus β-glucan, inulin, pectin and resistant starch, which has been shown to improve Child–Turcotte–Pugh classification and reduce encephalopathy,132 and to reduce bacterial infections after orthotopic liver transplantation;190 and (3) L plantarum 299V, which has been demonstrated to prevent infection after orthotopic liver transplantation in combination with fibre.189
Summary Box 2
The liver is a target of bacterial toll-like receptor (TLR) ligands due to its anatomical connection to the intestine.
Under normal circumstances, the liver is exposed to small amounts of bacterial pathogen-associated molecular patterns (PAMPs) but does not show signs of inflammation due to its higher tolerance to PAMPs and its ability to efficiently excrete PAMPs such as lipopolysaccharide (LPS).
In many types of chronic liver disease, levels of PAMPs are elevated. Most research has focused on LPS, and has shown increased LPS levels in chronic viral hepatitis, liver fibrosis and cirrhosis, and alcoholic liver disease.
LPS promotes liver injury and fibrogenesis under many circumstances. Blocking LPS release from the intestinal microbiota, or inhibiting activation and signalling of the LPS receptor TLR4 may therefore represent a feasible strategy for the prevention or treatment of chronic liver disease.
TLRs and downstream signalling molecules play a role in chronic viral hepatitis. Chronic hepatitis C virus infection leads to a downregulation of antiviral signalling pathways. Activation of specific TLR signals may booster antiviral immunity, and therefore represents a novel treatment approach for chronic viral hepatitis.
A second approach to reduce TLR ligands is the treatment with antibiotics to achieve selective intestinal decontamination of Gram-negative bacteria, the predominant source of LPS. Selective intestinal decontamination has been shown to reduce bacterial translocation in many but not all studies performed in rats.193–195 Importantly, norfloxacin administration reduced the 1 year probability of developing spontaneous bacterial peritonitis, hepatorenal syndrome, and improved the 3 month and 1 year probability of survival compared with placebo.196 While the reduction of spontaneous bacterial peritonitis in norfloxacin-treated patients is a direct consequence of reducing bacterial strains in the microbiota responsible for spontaneous peritonitis, some of the positive effect on mortality are likely spontaneous bacterial peritonitis (SBP)-independent and related to reducing bacterial translocation and circulating levels of TLR ligands.196 197 However, in view of the severe consequences of long-term antibiotics treatment, these treatment regimens will be reserved for selected high-risk patients with hepatic cirrhosis, and are not suited to reduce TLR agonists in patients with early stages of liver disease.
There is increasing evidence that TLRs play a key role in the pathophysiology of many chronic liver diseases. The possibility of targeting TLR signalling at different levels such as the intestinal microbiota, the level of TLRs, co-receptors such as MD2 and CD14 and downstream signalling molecules will open up new therapeutic options for the treatment of chronic liver disease. However, a number of issues regarding the role of the TLRs and their ligands in liver disease need to be addressed before TLRs can seriously be considered as pharmacological targets in liver disease.
First, the role of endogenous TLR ligands and their role in chronic liver disease needs to be investigated more thoroughly. Well-designed in vitro and in vivo studies using mice in which the release of these ligands is blocked or induced by genetic methods are required to avoid any issues with contaminating bacterial ligands.
Second, as a large number of cell types in the liver express TLRs, a better understanding of cell-specific functions is required, eg, by using cell-specific knockout strategies.
Third, the majority of studies on the role of TLRs in liver disease is based on animal models. Further translational research is required to firmly establish the role of TLRs in human liver disease.
Fourth, the potential therapeutic effect of TLR agonists, TLR antagonists and probiotics need to be further assessed in well-controlled animal and human studies. It is possible that targeting of TLRs by small molecule antagonists may have immunosuppressive effects, and they may have to be restricted to selective patient groups and exclude patient groups with advanced liver disease and immunosuppression.
Therefore, probiotics appear to be ideal candidates for the treatment of chronic liver disease such as alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD) and NASH, and liver fibrosis due to their high tolerability and limited side effects. However, it needs to be established whether the old pharmacological teaching that “no effect is to be expected from a drug that does not have side effects” is a rule with exceptions. Moreover, it would be interesting to determine whether the suppression of TLR signalling pathways by HCV can be blocked pharmacologically, and whether TLR agonists may have some effects on HBV and HCV that differ from those of interferon, and could thus provide a useful addition to current interferon-based therapies. We can anticipate that further research on TLR signalling in chronic liver disease will help to shape new concepts with the intestinal microbiota, TLRs and their downstream signalling mediators as pharmacological targets.
Funding: This study was supported by National Institute of Health grant R01 DK076920 (to RFS) and an American Liver Foundation postdoctoral research awarded (to JK).
Competing interests: None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.